[The new combined antituberculous drug: the original combined antituberculous drug dioxazid].
The new combined antituberculous drug dioxazid was designed on the basis on the synergism of isoniazid and dioxidine. The dosage form of the drug is a lyophilized powder (containing dioxidine, 100 mg, and isoniazid, 250 mg) in flasks. Its activity and toxicity were tested in an experiment on laboratory animals. Clinical studies were conducted in the treatment of patients with tuberculous empyema (n = 25) and those with endobronchial pathology of tuberculosis and comorbid genesis (n = 30). Dioxazid was ascertained to show a good efficacy. At the same time, the doses of this combined drug, recommended for the treatment of tuberculosis, are much smaller than those of both that are components of the combination, which are used alone. The side effects characteristic for each component are not potentiated when isoniazid and dioxidine are concurrently used in the developed dosage form.
Glushkov
R G
RG
Sokolova
G B
GB
Krylova
L Iu
LIu
Stebaeva
L F
LF
Sharova
S A
SA
D000818:Animals; D000995:Antitubercular Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D007538:Isoniazid / Q000627:therapeutic use*; D008297:Male; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D011810:Quinoxalines / Q000627:therapeutic use*; D051381:Rats; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology
D000995:Antitubercular Agents; D004338:Drug Combinations; D011810:Quinoxalines; C513230:dioxazid; D007538:Isoniazid